BFM
AUTL icon

Boothbay Fund Management’s Autolus Therapeutics AUTL Stock Holding History

Boothbay Fund Management’s Portfolio AUTL Stock Details AUTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-29,822
Closed -$192K – 1583
2023
Q4 		$192K Hold
29,822
– – ﹤0.01% 1341
2023
Q3 		$69.5K Buy
29,822
+2,607
+10% +$7.43K ﹤0.01% 1602
2023
Q2 		$64.8K Hold
27,215
– – ﹤0.01% 1661
2023
Q1 		$50.1K Hold
27,215
– – ﹤0.01% 2021
2022
Q4 		$51.7K Hold
27,215
– – ﹤0.01% 1872
2022
Q3 		$58K Sell
27,215
-4,963
-15% -$14.7K ﹤0.01% 2100
2022
Q2 		$91K Sell
32,178
-4,993
-13% -$15.2K ﹤0.01% 1999
2022
Q1 		$155K Sell
37,171
-19,972
-35% -$84K ﹤0.01% 1978
2021
Q4 		$297K Sell
57,143
-39,281
-41% -$236K 0.01% 1262
2021
Q3 		$632K Sell
96,424
-95,396
-50% -$603K 0.02% 978
2021
Q2 		$1.27M Buy
191,820
+41,908
+28% +$260K 0.04% 579
2021
Q1 		$859K Buy
+149,912
New +$1.11M 0.03% 679
2019
Q1 		– Sell
-8,000
Closed -$263K – 744
2018
Q4 		$263K Buy
+8,000
New +$263K 0.04% 419

Other funds holding AUTL

SP
Syncona Portfolio St Peter Port, Guernsey $26.6M AUM 10.36% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $39B AUM 18.55% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
TAM
TFG Asset Management Grand Cayman, Cayman Islands $635M AUM 28.07% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Boothbay Fund Management's AUTL Position: Q1 2024 in Review

Boothbay Fund Management sold out of Autolus Therapeutics (AUTL) in Q1 2024, closing a stake of 29,822 shares — an estimated $192K sold.

Boothbay Fund Management first reported a position in AUTL in Q4 2018 and held it in 13 quarters. The position peaked at $1.27M in Q2 2021. 121 funds tracked by Wall St. Rank hold AUTL as of Q1 2024.

  • Boothbay Fund Management reported no remaining Autolus Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Boothbay Fund Management sold 29,822 Autolus Therapeutics shares in Q1 2024, an estimated $192K.
  • Boothbay Fund Management first reported a position in Autolus Therapeutics in Q4 2018 and held it in 13 quarters.
  • Boothbay Fund Management's Autolus Therapeutics position peaked at $1.27M in Q2 2021.
  • 121 funds tracked by Wall St. Rank held Autolus Therapeutics as of Q1 2024.

Based on Boothbay Fund Management's 13F filing for Q1 2024, filed 15 May 2024.